Research progress of SIRT1 in the pathogenesis of diabetic cardiomyopathy

doi:10.11958/20231289

Abstract

Abstract:

Diabetic cardiomyopathy (DCM) is one of the most serious cardiovascular complications in diabetic patients, and it is also the main cause of increased mortality in diabetic patients, which has become a major global public health problem. As an important intracellular regulatory protein in body, sirtuin 1 (SIRT1) plays an important role in many biological processes, including reducing oxidative stress in cardiomyocytes, maintaining Ca²⁺ homeostasis in myocardial mitochondria, reducing myocardial endoplasmic reticulum stress, improving myocardial mitochondrial dysfunction, and inhibiting the activation of renin-angiotensin-aldosterone system. SIRT1 may be a potential therapeutic target for DCM. Further research targeting SIRT1 can provide a new theoretical basis for the clinical treatment of DCM. This article reviews the specific role of SIRT1 in the pathogenesis and treatment strategies of DCM.

Key words: diabetes mellitus, diabetic cardiomyopathies, sirtuin 1, oxidative stress, mitochondria, endoplasmic reticulum stress, renin-angiotensin-aldosterone system

CLC Number:

R587.23

Figures/Tables 2

References 40

[1]	SUN H, SAEEDI P, KARURANGA S, et al. IDF Diabetes Atlas:Global,regional and country-level diabetes prevalence estimates for 2021 and projections for 2045[J]. Diabetes Res Clin Pract, 2022, 183:109119. doi:10.1016/j.diabres.2021.109119.
[2]	American Diabetes Association Professional Practice Committee. Cardiovascular disease and risk management:standards of medical care in diabetes-2022[J]. Diabetes Care, 2022, 45(Suppl 1):S144-S174. doi:10.2337/dc22-S010.
[3]	PAN K L, HSU Y C, CHANG S T, et al. The role of cardiac fibrosis in diabetic cardiomyopathy:from pathophysiology to clinical diagnostic tools[J]. Int J Mol Sci, 2023, 24(10):8604. doi:10.3390/ijms24108604.
[4]	COSTANTINO S, MENGOZZI A, VELAGAPUDI S, et al. Treatment with recombinant Sirt1 rewires the cardiac lipidome and rescues diabetes-related metabolic cardiomyopathy[J]. Cardiovasc Diabetol, 2023, 22(1):312. doi:10.1186/s12933-023-02057-2.
[5]	SUN C, LIANG H, ZHAO Y, et al. Jingfang Granules improve glucose metabolism disturbance and inflammation in mice with urticaria by up-regulating LKB1/AMPK/SIRT1 axis[J]. J Ethnopharmacol, 2023, 302(Pt A):115913. doi:10.1016/j.jep.2022.115913.
[6]	YANCY C W, JESSUP M, BOZKURT B, et al. 2013 ACCF/AHA guideline for the management of heart failure:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J]. J Am Coll Cardiol, 2013, 62(16):e147-e239. doi:10.1016/j.jacc.2013.05.019.
[7]	MAISCH B, ALTER P, PANKUWEIT S. Diabetic cardiomyopathy--fact or fiction?[J]. Herz, 2011, 36(2):102-115. doi:10.1007/s00059-011-3429-4.
[8]	WANG A J, WANG S, WANG B J, et al. Epigenetic regulation associated with sirtuin 1 in complications of diabetes mellitus[J]. Front Endocrinol(Lausanne), 2021, 11:598012. doi:10.3389/fendo.2020.598012.
[9]	FANG W J, LI X M, ZHOU X K, et al. Resveratrol improves diabetic cardiomyopathy by preventing asymmetric dimethylarginine-caused peroxisome proliferator-activated receptor-γ coactivator-1α acetylation[J]. Eur J Pharmacol, 2022, 936:175342. doi:10.1016/j.ejphar.2022.175342.
[10]	WALDMAN M, COHEN K, YADIN D, et al. Regulation of diabetic cardiomyopathy by caloric restriction is mediated by intracellular signaling pathways involving 'SIRT1 and PGC-1α'[J]. Cardiovasc Diabetol, 2018, 17(1):111. doi:10.1186/s12933-018-0754-4.
[11]	DU S, SHI H, XIONG L, et al. Canagliflozin mitigates ferroptosis and improves myocardial oxidative stress in mice with diabetic cardiomyopathy[J]. Front Endocrinol(Lausanne), 2022, 13:1011669. doi:10.3389/fendo.2022.1011669.
[12]	DAIBER A, STEVEN S, VUJACIC-MIRSKI K, et al. Regulation of vascular function and inflammation via cross talk of reactive oxygen and nitrogen species from mitochondria or NADPH oxidase-implications for diabetes progression[J]. Int J Mol Sci, 2020: 21(10):3405. doi:10.3390/ijms21103405.
[13]	ZHANG W, CHEN R, XU K, et al. Protective effect of Xinmai'an tablets via mediation of the AMPK/SIRT1/PGC-1α signaling pathway on myocardial ischemia-reperfusion injury in rats[J]. Phytomedicine, 2023, 120:155034. doi:10.1016/j.phymed.2023.155034.
[14]	LI K, ZHAI M, JIANG L, et al. Tetrahydrocurcumin ameliorates diabetic cardiomyopathy by attenuating high glucose-induced oxidative stress and fibrosis via activating the SIRT1 pathway[J]. Oxid Med Cell Longev, 2019: 2019:6746907. doi:10.1155/2019/6746907.
[15]	DUAN J, YIN Y, WEI G, et al. Chikusetsu saponin IVa confers cardioprotection via SIRT1/ERK1/2 and Homer1a pathway[J]. Sci Rep, 2015, 5:18123. doi:10.1038/srep18123.
[16]	DATTA S, JAISWAL M. Mitochondrial calcium at the synapse[J]. Mitochondrion, 2021, 59:135-153. doi:10.1016/j.mito.2021.04.006.
[17]	DIAZ-JUAREZ J, SUAREZ J, CIVIDINI F, et al. Expression of the mitochondrial calcium uniporter in cardiac myocytes improves impaired mitochondrial calcium handling and metabolism in simulated hyperglycemia[J]. Am J Physiol Cell Physiol, 2016, 311(6):C1005-C1013. doi:10.1152/ajpcell.00236.2016.
[18]	SUAREZ J, CIVIDINI F, SCOTT B T, et al. Restoring mitochondrial calcium uniporter expression in diabetic mouse heart improves mitochondrial calcium handling and cardiac function[J]. J Biol Chem, 2018, 293(21):8182-8195. doi:10.1074/jbc.RA118.002066.
[19]	DIA M, GOMEZ L, THIBAULT H, et al. Reduced reticulum-mitochondria Ca²⁺ transfer is an early and reversible trigger of mitochondrial dysfunctions in diabetic cardiomyopathy[J]. Basic Res Cardiol, 2020, 115(6):74. doi:10.1007/s00395-020-00835-7.
[20]	GORSKI P A, JANG S P, JEONG D, et al. Role of SIRT1 in modulating acetylation of the sarco-endoplasmic reticulum Ca²⁺-ATPase in heart failure[J]. Circ Res, 2019, 124(9):e63-e80. doi:10.1161/CIRCRESAHA.118.313865.
[21]	VILELLA R, IZZO S, NAPONELLI V, et al. In vivo treatment with a standardized green tea extract restores cardiomyocyte contractility in diabetic rats by improving mitochondrial function through SIRT1 activation[J]. Pharmaceuticals(Basel), 2022, 15(11):1337. doi:10.3390/ph15111337.
[22]	HUANG Q, LIU Z, YANG Y, et al. Selenium nanodots(SENDs)as antioxidants and antioxidant-prodrugs to rescue islet β cells in type 2 diabetes mellitus by restoring mitophagy and alleviating endoplasmic reticulum stress[J]. Adv Sci (Weinh), 2023, 10(19):e2300880. doi:10.1002/advs.202300880.
[23]	AL KURY L T. Calcium homeostasis in ventricular myocytes of diabetic cardiomyopathy[J]. J Diabetes Res, 2020, 2020:1942086. doi:10.1155/2020/1942086.
[24]	YANG S, WU M, LI X, et al. Role of endoplasmic reticulum stress in atherosclerosis and its potential as a therapeutic target[J]. Oxid Med Cell Longev, 2020, 2020:9270107. doi:10.1155/2020/9270107.
[25]	MA S, FENG J, ZHANG R, et al. SIRT1 activation by resveratrol alleviates cardiac dysfunction via mitochondrial regulation in diabetic cardiomyopathy mice[J]. Oxid Med Cell Longev, 2017, 2017:4602715. doi:10.1155/2017/4602715.
[26]	PROLA A, PIRES DA SILVA J, GUILBERT A, et al. SIRT1 protects the heart from ER stress-induced cell death through eIF2α deacetylation[J]. Cell Death Differ, 2017, 24(2):343-356. doi:10.1038/cdd.2016.138.
[27]	REN F F, XIE Z Y, JIANG Y N, et al. Dapagliflozin attenuates pressure overload-induced myocardial remodeling in mice via activating SIRT1 and inhibiting endoplasmic reticulum stress[J]. Acta Pharmacol Sin, 2022, 43(7):1721-1732. doi:10.1038/s41401-021-00805-2.
[28]	JIA G, DEMARCO V G, SOWERS J R. Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy[J]. Nat Rev Endocrinol, 2016, 12(3):144-153. doi:10.1038/nrendo.2015.216.
[29]	PANES J D, GODOY P A, SILVA-GRECCHI T, et al. Changes in PGC-1α/SIRT1 signaling impact on mitochondrial homeostasis in amyloid-beta peptide toxicity model[J]. Front Pharmacol, 2020, 11:709. doi:10.3389/fphar.2020.00709.
[30]	DIAO J, ZHAO H, YOU P, et al. Rosmarinic acid ameliorated cardiac dysfunction and mitochondrial injury in diabetic cardiomyopathy mice via activation of the SIRT1/PGC-1α pathway[J]. Biochem Biophys Res Commun, 2021, 546:29-34. doi:10.1016/j.bbrc.2021.01.086.
[31]	DING M, FENG N, TANG D, et al. Melatonin prevents Drp1-mediated mitochondrial fission in diabetic hearts through SIRT1-PGC1α pathway[J]. J Pineal Res, 2018, 65(2):e12491. doi:10.1111/jpi.12491.
[32]	GRUBIĆ ROTKVIĆ P, PLANINIĆ Z, LIBERATI PRŠO A M, et al. The mystery of diabetic cardiomyopathy:from early concepts and underlying mechanisms to novel therapeutic possibilities[J]. Int J Mol Sci, 2021, 22(11):5973. doi:10.3390/ijms22115973.
[33]	SHEN J Z, YOUNG M J. Corticosteroids,heart failure,and hypertension:a role for immune cells?[J]. Endocrinology, 2012, 153(12):5692-5700. doi:10.1210/en.2012-1780.
[34]	WAHBA N S, GHAREIB S A, ABDEL-GHANY R H, et al. Vitamin D3 potentiates the nephroprotective effects of metformin in a rat model of metabolic syndrome:role of AMPK/SIRT1 activation and DPP-4 inhibition[J]. Can J Physiol Pharmacol, 2021, 99(6):685-697. doi:10.1139/cjpp-2020-0435.
[35]	WEN J, ZHANG L, WANG J, et al. Therapeutic effects of higenamine combined with [6]-gingerol on chronic heart failure induced by doxorubicin via ameliorating mitochondrial function[J]. J Cell Mol Med, 2020, 24(7):4036-4050. doi:10.1111/jcmm.15041.
[36]	JIN Q, ZHU Q, WANG K, et al. Allisartan isoproxil attenuates oxidative stress and inflammation through the SIRT1/Nrf2/NF-κB signalling pathway in diabetic cardiomyopathy rats[J]. Mol Med Rep, 2021, 23(3):215. doi:10.3892/mmr.2021.11854.
[37]	WEN Y, GENG L, ZHOU L, et al. Betulin alleviates on myocardial inflammation in diabetes mice via regulating Siti1/NLRP3/NF-κB pathways[J]. Int Immunopharmacol, 2020, 85:106653. doi:10.1016/j.intimp.2020.106653.
[38]	REN B C, ZHANG Y F, LIU S S, et al. Curcumin alleviates oxidative stress and inhibits apoptosis in diabetic cardiomyopathy via Sirt1-Foxo1 and PI3K-Akt signalling pathways[J]. J Cell Mol Med, 2020, 24(21):12355-12367. doi:10.1111/jcmm.15725.
[39]	MA W, GUO W, SHANG F, et al. Bakuchiol alleviates hyperglycemia-induced diabetic cardiomyopathy by reducing myocardial oxidative stress via activating the SIRT1/Nrf2 signaling pathway[J]. Oxid Med Cell Longev, 2020, 2020:3732718. doi:10.1155/2020/3732718.
[40]	ALBASHER G, ALKAHTANI S, AL-HARBI L N. Urolithin A prevents streptozotocin-induced diabetic cardiomyopathy in rats by activating SIRT1[J]. Saudi J Biol Sci, 2022, 29(2):1210-1220. doi:10.1016/j.sjbs.2021.09.045.

DCM分期	临床表现
1期	心脏舒张功能异常但射血分数正常^#
2期	心脏收缩和舒张功能共同受损
3期	收缩期和舒张期功能障碍伴有微血管疾病/非梗阻性冠状动脉粥样硬化症
4期	临床明显的心肌缺血/梗死引发心力衰竭

DCM分期	临床表现
1期	心脏舒张功能异常但射血分数正常^#
2期	心脏收缩和舒张功能共同受损
3期	收缩期和舒张期功能障碍伴有微血管疾病/非梗阻性冠状动脉粥样硬化症
4期	临床明显的心肌缺血/梗死引发心力衰竭

研究对象	NCT号	临床阶段	样本量	干预手段	研究目的	状态
DCM	04141475	未知	100	α-硫辛酸	治疗前后左室射血分数变化	未知
DCM	04083339	Ⅲ期	675	AT-001	心肺运动试验期间的峰值摄氧量	正在进行
DCM	05556005	Ⅱ期	60	曲美他嗪	与基线相比的变化3个月时的左心室功能	正在招募受试者
肥胖（DM/DM高风险）患者	01067209	未知	45	胃旁路手术	心脏功能，心肌脂肪沉积	正在进行
DCM	04200586	Ⅳ期	30	达格列净	心肌灌注储备指数变化	正在进行
EF降低的DM心力衰竭患者	04304560	Ⅱ期	60	达格列净	达格列净对2型糖尿病患者心肌病发病率和死亡率的影响	未知

研究对象	NCT号	临床阶段	样本量	干预手段	研究目的	状态
DCM	04141475	未知	100	α-硫辛酸	治疗前后左室射血分数变化	未知
DCM	04083339	Ⅲ期	675	AT-001	心肺运动试验期间的峰值摄氧量	正在进行
DCM	05556005	Ⅱ期	60	曲美他嗪	与基线相比的变化3个月时的左心室功能	正在招募受试者
肥胖（DM/DM高风险）患者	01067209	未知	45	胃旁路手术	心脏功能，心肌脂肪沉积	正在进行
DCM	04200586	Ⅳ期	30	达格列净	心肌灌注储备指数变化	正在进行
EF降低的DM心力衰竭患者	04304560	Ⅱ期	60	达格列净	达格列净对2型糖尿病患者心肌病发病率和死亡率的影响	未知